New drug eases shift work disorder, boosting alertness and safety for early-morning crews

In a double‑blind trial conducted at three hospitals in the United States, 120 early‑morning shift workers with diagnosed shift work disorder took solriamfetol or placebo before their 4 a.m. start. The fluorescent lights hummed overhead as participants, still half‑asleep, hesitated before swallowing the capsule, aware that their performance would be measured against a full eight‑hour shift.

How solriamfetol improves early‑morning performance

The medication increased wakefulness scores by 30 percent on average, allowing workers to stay alert through routine tasks and emergency responses. Participants reported clearer thinking, steadier hands, and a reduced need for coffee, a fact underscored by the metallic clang of the break‑room kettle that no longer punctuated their lapses.

Balancing safety and productivity

This outcome highlights a structural tension: the drive for higher productivity often compresses safety margins, yet the trial shows a pharmacological tool can expand both. By mitigating fatigue, solriamfetol not only lifts output but also lowers the risk of errors that endanger patients and colleagues.

The findings matter because they offer a tangible way to protect workers and the public from fatigue‑related mistakes.

As society runs around the clock, safeguarding alertness becomes a public priority.